Corneal cross-linking is now available at the Bay Area Eye Institute
Avedro, Inc., an ophthalmic pharmaceutical and medical device company, recently received FDA approval for corneal cross-linking, a medical procedure that combines the use of ultra-violet (UV) light and riboflavin (vitamin B2) eye drops.
Dr. Craig Berger is excited to announce the recent approval of this minimally invasive treatment, corneal collagen cross-linking for keratoconus! Corneal collagen cross-linking is NOW AVAILABLE at the Bay Area Eye Institute in Tampa, Florida.
Corneal Collagen Cross-Linking:
- Creates new corneal collagen cross-links
- Results in a shortening and thickening of the collagen fibrils
- Leads to the stiffening of the cornea
Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved.
Since the only FDA-approved procedure is Avedro’s KXL System with Photrexa, only this device and drug use could be considered “off label” for Epi On. Any other drug/device combination for CXL is non-FDA approved and not considered “off label.”
The only clinical trials allowed are investigational studies under an FDA approved IND. An IRB alone is not sufficient.
Billing J2787 with products other than Avedro, could be considered insurance fraud. Insurance policies generally state that only FDA approved products are covered.
It is important to understand the difference between approved, off label, and not approved. An unapproved product cannot be considered to be used in an off label fashion, as there is no label.
Doctor Berger is now offering corneal collagen cross-linking , the only FDA-approved therapeutic treatment for progressive keratoconus, to his Tampa Bay area keratoconus patients. Book an appointment with Dr. Berger to find out if corneal cross-linking is right for you.